Extended Data Fig. 3: CA-CypA interaction promotes HIV-1 transduction by inhibiting TRIM5 activity in primary human blood cells.
From: Cyclophilin A protects HIV-1 from restriction by human TRIM5α
a, Raw infectivity data for single cycle viruses, before normalization of infectivity to control condition. Shown are representative of three independent experiments using cells from three blood donors for each condition. b, Macrophages expressing shRNA targeting TRIM5 or Luc were challenged with single-cycle, VSV G-pseudotyped, HIV-1NL4-3GFP in the presence of 8 µM CsA, 8 µM CsH, or DMSO solvent (mean ± SEM, n = 2 donors). c and d, TRIM5 or Luc knockdown CD4+ T cells were challenged with single-cycle HIV-1NL4-3GFP (c) or HIV-1Z331M-TFGFP (d) in the presence of 2.5 µM GS-CypAi3 or DMSO solvent alone (mean ± SEM, n = 3 donors for each). e, HIV-1NL4-3GFP was used to challenge TRIM5 or Luc knockdown CD4+ T cells with 2.5 µM GS-CypAi48 or DMSO solvent alone (mean ± SEM, n = 2 donors). Flow cytometry was used to measure the percentage of GFP+ cells, followed by normalization to WT in Luc knockdown cells. Significance was determined by two-tailed, paired t- test for data generated with at least three donors (n = 3).
